Endometrial cancer prognosis in women with endometriosis and adenomyosis: A retrospective nationwide cohort study of 40 840 women.
adenomyosis
endometrial cancer
endometriosis
prognosis
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
revised:
13
12
2021
received:
24
08
2021
accepted:
14
12
2021
pubmed:
19
12
2021
medline:
29
4
2022
entrez:
18
12
2021
Statut:
ppublish
Résumé
We aim to compare endometrial cancer survival in women with or without histological proven endometriosis or adenomyosis. We identified all women with endometrial cancer between 1990 and 2015 from the Netherlands Cancer Registry (NCR). Data were linked to the Dutch pathology database (PALGA) to select all women with histological proven endometriosis/adenomyosis. Overall survival was compared between women with endometrial cancer with or without endometriosis/adenomyosis. We used multivariable Cox proportional hazard analysis to estimate hazard ratios (HRs). We included 1701 women with endometrial cancer and endometriosis/adenomyosis, of whom 1236 (72.7%) women had adenomyosis, 320 (18.8%) had endometriosis and 145 (8.5%) had both. We compared these women to 39 139 women with endometrial cancer without endometriosis/adenomyosis. Women in the combined endometriosis/adenomyosis cohort were younger at endometrial cancer diagnosis, had earlier disease stage, more often had endometrioid endometrial cancer and low grade tumors. The 5-year survival rate in the combined endometriosis/adenomyosis cohort was 84.8% (95% CI 84.6-88.1) and 71.6% (95% CI 71.1-72.0) in the nonendometriosis/adenomyosis cohort. Univariable analysis resulted in a crude HR of 0.63 (95% CI 0.59-0.69). Significant confounding factors were age, stage, cancer subtype, histological grading, surgery and chemotherapy rate. Correction for these confounders resulted in a HR of 0.98 (95% CI 0.90-1.06). Including endometriosis/adenomyosis status as a categorical factor resulted in similar HRs. In conclusion, women with endometrial cancer and histologically proven endometriosis/adenomyosis have a better overall survival when compared to women with endometrial cancer without endometriosis/adenomyosis. This better survival was correlated to stage, grade, age and histological subtype, but not to the presence of endometriosis/adenomyosis.
Identifiants
pubmed: 34921730
doi: 10.1002/ijc.33907
pmc: PMC9303796
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1439-1446Informations de copyright
© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Cancers (Basel). 2021 Sep 13;13(18):
pubmed: 34572823
Int J Cancer. 2022 May 1;150(9):1439-1446
pubmed: 34921730
Ir J Med Sci. 2020 Aug;189(3):835-842
pubmed: 31970616
Sci Rep. 2020 Feb 27;10(1):3621
pubmed: 32108150
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1132-42
pubmed: 15894663
J Obstet Gynaecol Res. 2020 Sep;46(9):1851-1863
pubmed: 32686169
Cancer Sci. 2020 Oct;111(10):3458-3467
pubmed: 32654393
Hum Reprod. 2014 Mar;29(3):400-12
pubmed: 24435778
Cancer Detect Prev. 2004;28(2):94-8
pubmed: 15068832
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 2005 Aug 6-12;366(9484):491-505
pubmed: 16084259
In Vivo. 2019 May-Jun;33(3):659-667
pubmed: 31028182
Gynecol Oncol. 2016 Oct;143(1):87-92
pubmed: 27430396
Mol Hum Reprod. 2006 Dec;12(12):737-48
pubmed: 17020905
Hum Reprod Update. 2021 Feb 19;27(2):393-420
pubmed: 33202017
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
Adv Anat Pathol. 2004 May;11(3):117-42
pubmed: 15096727
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50
pubmed: 30306580